Oncology
The latest news about Oncology: headlines, AI summaries and the full story from every source.
- Olema Pharmaceuticals Reports Third Quarter GAAP EPS Miss
- Coherus BioSciences Outlines Cost-Saving Measures and Revised Cash Burn Targets
- Moderna Upgrades 2026 Revenue Guidance Following Positive Phase 3 Cancer Vaccine Results
- Gilead Sciences Maintains 11-Year Dividend Growth Streak Supported by HIV and Oncology Revenue
- Vir Biotechnology Projects Cash Runway into Second Half of 2028 Amid Key Clinical Milestones
- Nuvation Bio Reports Third Quarter Revenue of $45 Million, Exceeding Estimates
- AstraZeneca Reports Revenue Growth Driven by Oncology Expansion and Restructuring Initiatives
- AstraZeneca Reports Q3 2026 Results with Strong Oncology and Rare Disease Growth
- NCODA Announces Inaugural Clinical Advances Summit for October 2027
- Gilead Sciences Reports Strong Q3 2026 Results Driven by HIV and Oncology Growth
- CareDx Raises 2026 Revenue Guidance Amid Expansion into Oncology and Cell Therapy
- Daiichi Sankyo Reports 19.7% Revenue Growth in Q2 Driven by Oncology Portfolio
- Iovance Biotherapeutics Shares Drop 34% Following Phase 2 Amtagvi Data for Lung Cancer
- Merck Projects 2026 Revenue Between $66.8B and $67.3B Amid Keytruda Transition Strategy
- Bicycle Therapeutics Reports Q3 Earnings Beat with Significant Revenue Growth
- Genmab Shares Surge Following Positive Phase 3 Trial Results for Petosemtamab
- AstraZeneca Explores Development of mRNA Cancer Vaccines
- Bristol Myers Squibb Reports Positive Phase 3 Trial Results for Lung Cancer Drug Iza-bren
- FDA Approves Pfizer's Talzenna and Xtandi Combination for Metastatic Hormone-Sensitive Prostate Cancer
- Xencor Shares Rise 16% Following Positive Early Clinical Data for XmAb819
- Merck's sacituzumab tirumotecan Reduces Death Risk by 32% in Endometrial Cancer Phase 3 Trial
- Celcuity Reports Improved Progression-Free Survival with Revtorpyk in Phase 3 Breast Cancer Trial
- Johnson & Johnson Reports 75% Tumor Response Rate in Early-Stage Prostate Cancer Trial
- Amgen's Imdelltra Combination Therapy Reduces Death Risk by 58% in Extensive-Stage Small Cell Lung Cancer
- ESMO Congress Highlights Oncology Breakthroughs Amid Market Volatility and Fed Uncertainty
- Arcus Biosciences Shares Drop 20% Following Stock Offering and Kidney Cancer Clinical Data
- European Commission Approves Merck and Pfizer/Astellas Combination Therapy for Bladder Cancer
- Cencora Announces Agreement to Acquire American Oncology Network for $2.4 Billion
- Verastem's VS-7375 Shows Strong Anti-Tumor Activity in KRAS G12D-Mutant Cancers
- Genmab and AbbVie Report Positive Phase 3 Trial Results for Epkinly in B-cell Lymphoma
- BoomRay Pharmaceuticals Enters into $900M Deal with Novartis for Radioligand Therapy
- GSK Aims for £40 Billion Sales Target with Oncology Growth and Cost-Saving Plan
- Cencora's Specialty Strategy Expected to Drive Growth Through Fiscal 2027
- Guardant Health Gains FDA Approval for Guardant360 CDx, Boosting Investor Confidence
- AbbVie partners with Iambic Therapeutics on multi-year AI drug discovery collaboration
- McKesson Raises Full-Year Earnings Outlook and Announces Precision Medicine Acquisition
- BridgeBio Oncology Therapeutics Narrows Focus on KRASG12C Inhibitor Combinations
- OncoHost to Present New Data on PROphetNSCLC at WCLC 2026
- McKesson to Acquire Precision Medicine Group for $2.25 Billion
- Pyxis Oncology Appoints Thomas Civik as CEO and Chairman
- McKesson Acquires Precision Medicine Group for $2.25 Billion to Bolster Oncology Division
- Thyme Care Raises $125 Million in Series E Funding at Over $2 Billion Valuation
- Thyme Care Secures Over $125M Series E Funding at a Valuation Exceeding $2B
- McKesson Acquires Precision Medicine Group for $2.25 Billion
- Revolution Medicines Achieves FDA Approval for Rasonque, Reaching $47B Valuation
- Guardant Health Reports Strong Q2 2026 Performance and Raises Full-Year Revenue Guidance
- AbbVie Inc. Reports Strong Q2 2026 Performance with Growth Across Key Portfolios
- Eisai Grants Core Biomedicine Global License to Oncology Pipeline
- CORE Biomedicine Licenses Precision Oncology Programs from Eisai
- AstraZeneca Reports Strong Q2 Earnings, Exceeds Expectations